Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody

British Journal of Pharmacology

Volumn 168, Issue 3, 2013, Pages 658-672

  Chen, Kuen Feng ^a,b   Chen, Hui Ling ^a   Shiau, Chung Wai ^d   Liu, Chun Yu ^c,d   Chu, Pei Yi ^e   Tai, Wei Tien ^a   Ichikawa, Kimihisa ^f   Chen, Pei Jer ^a   Cheng, Ann Lii ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e St Martin De Porres Hospital   (Taiwan)

^f DAIICHI SANKYO CO   (Japan)

Author keywords

CS 1008; HCC; SC 49; sorafenib; STAT3

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLIN D1; PROTEIN MCL 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; SCANDIUM 49; SORAFENIB; STAT3 PROTEIN; SURVIVIN; TIGATUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84984558781     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02212.x     Document Type: Article

References (54)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Adnane L, Trail PA, Taylor I, Wilhelm SM, (2006). Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612.
3. Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, et al. (2007). Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21: 439-445.
4. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ, (2009). Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 50: 1861-1870.
5. Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R, et al. (2003). Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 17: 379-389.
6. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL, (2008). Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707.
7. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, et al. (2009). Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284: 11121-11133.
8. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, et al. (2010). Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16: 5189-5199.
9. Chen KF, Tai WT, Huang JW, Hsu CY, Chen WL, Cheng AL, et al. (2011). Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem 46: 2845-2851.
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
11. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, et al. (2001). Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319.
12. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I, (2003). TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22: 3842-3852.
13. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H, (2009). TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 647: 195-206.
14. Fulda S, Meyer E, Debatin KM, (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294.
15. Germain D, Frank DA, (2007). Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13: 5665-5669.
16. Hall MA, Cleveland JL, (2007). Clearing the TRAIL for cancer therapy. Cancer Cell 12: 4-6.
17. Huang S, Sinicrope FA, (2010). Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 9: 742-750.
18. Johnstone RW, Frew AJ, Smyth MJ, (2008). The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798.
19. Ke Y, Zhang EE, Hagihara K, Wu D, Pang Y, Klein R, et al. (2007). Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol 27: 6706-6717.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
21. Kim SH, Ricci MS, El-Deiry WS, (2008). Mcl-1: a gateway to TRAIL sensitization. Cancer Res 68: 2062-2064.
22. Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR, et al. (2009). TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 15: 5924-5935.
23. Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB, (2009). Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res 7: 118-128.
24. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, et al. (2007). Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 47: 546-555.
25. Li H, Zhu H, Xu CJ, Yuan J, (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501.
26. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, et al. (2006). Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 12: 7140-7148.
27. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858.
28. Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, et al. (2010). The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46: 836-850.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
30. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reportingexperiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, et al. (2007). Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 282: 29831-29846.
32. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, et al. (2003). Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043.
33. Pandey MK, Sung B, Ahn KS, Aggarwal BB, (2009). Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol Pharmacol 75: 525-533.
34. Passmore JS, Lukey PT, Ress SR, (2001). The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell function. Immunology 102: 146-156.
35. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, et al. (2006). HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43: 425-434.
36. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. (2007). Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80.
37. Rowinsky EK, (2005). Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23: 9394-9407.
38. Saleh MN, Percent I, Wood TE, Posey J III, Shah J, Carlisle R, et al. (2008). A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. J Clin Oncol 26: 3537.
39. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, et al. (2002). Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34: 114-122.
40. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, et al. (2011). Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 55: 1041-1048.
41. Tanaka S, Arii S, (2009). Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100: 1-8.
42. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, et al. (2004). Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64: 3517-3524.
43. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al. (2009). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20 (Suppl 7): vii1-vii6.
44. Wang JM, Lai MZ, Yang-Yen HF, (2003). Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol Cell Biol 23: 1896-1909.
45. Wang S, (2008). The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27: 6207-6215.
46. Wang S, El-Deiry WS, (2003). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633.
47. Wiezorek J, Holland P, Graves J, (2010). Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 16: 1701-1708.
48. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844.
49. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, et al. (2008). A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 19: 1060-1067.
50. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, et al. (2008). Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 7: 3519-3526.
51. Yang-Yen HF, (2006). Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci 13: 201-204.
52. Zhang L, Fang B, (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237.
53. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, et al. (2010). Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16: 3420-3430.
54. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P, (2001). Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 61: 7339-7348.